Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anthera Pharmaceuticals IncANTH · Entity 163677 | Chief Technology Officer | May 20, 2017 | May 22, 2017 |
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anthera Pharmaceuticals Inc
Report date May 20, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2027-05-20 | Direct | 43,750 |
Reported balance
After 2017-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-20 · Grant · Acquired 43,750 · Balance 43,750 F1: This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027.
Edesa Biotech, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 19,000 · Balance 30,000 F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003799 · ownership.xml · nonDerivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:29 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003592 · ownership.xml · nonDerivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009528 · section16.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2023-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:56 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009605 · section16.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:35 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013778 · tv516186_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:21 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014754 · tv488522_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| May 20, 2017 Filed May 22, 2017 20:45 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GrantStock option (right to buy) · Derivative | 43,750 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001214659-17-003556 · marketforms-38874.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2027-05-20 F1 · derivative.exercise_date: This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:02 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016845 · v462725_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| January 11, 2017 Filed Feb 6, 2017 18:33 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GrantCommon Stock | 7,767 | $0.55 | $4,271.85 |
DisclosureSEC source: 0001214659-17-000746 · marketforms-37769.xml · nonDerivative · entry 2 Olson Charles V · CIK 0001663298 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,519 F2 · kind: Represents 7,767 shares acquired under the Issuer's 2010 Employee Stock Purchase Plan for the offering period ended December 31, 2016. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 22:02 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001144204-16-140714 · v455478_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2023-12-20 F1 · derivative.exercise_date: Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third on December 20, 2017, as to one-third on December 20, 2018 and as to the remaining one-third on December 20, 2019. Read SEC document |
| June 30, 2016 Filed Feb 6, 2017 18:33 UTC | Anthera Pharmaceuticals Inc ANTH · Entity 163677 | GrantCommon Stock | 1,789 | $2.63 | $4,705.07 |
DisclosureSEC source: 0001214659-17-000746 · marketforms-37769.xml · nonDerivative · entry 1 Olson Charles V · CIK 0001663298 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,752 F1 · kind: Represents 1,789 shares acquired under the Issuer's 2010 Employee Stock Purchase Plan for the offering period ended June 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.